Comment
doi: 10.1016/S0140-6736(20)31793-1.
Epub 2020 Aug 29.
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy
Affiliations
- PMID: 32871101
- DOI: 10.1016/S0140-6736(20)31793-1
Item in Clipboard
Comment
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy
Lancet.
.
No abstract available
Comment on
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Lancet. 2020. PMID: 32871100 Clinical Trial.
Similar articles
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15. Lancet. 2021. PMID: 34004177 Clinical Trial.
-
Mavacamten for hypertrophic obstructive cardiomyopathy.Lancet. 2021 Jan 30;397(10272):369. doi: 10.1016/S0140-6736(20)32384-9. Lancet. 2021. PMID: 33516331 No abstract available.
-
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.Clin Nurse Spec. 2024 May-Jun 01;38(3):E3. doi: 10.1097/NUR.0000000000000822. Clin Nurse Spec. 2024. PMID: 38625808 No abstract available.
-
Mavacamten: First Approval.Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 8. Drugs. 2022. PMID: 35802255 Free PMC article. Review.
-
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy.Med. 2024 Jul 12;5(7):655-659. doi: 10.1016/j.medj.2024.06.001. Med. 2024. PMID: 39002536 Review.
Cited by
-
Computational analysis of ventricular mechanics in hypertrophic cardiomyopathy patients.Sci Rep. 2023 Jan 18;13(1):958. doi: 10.1038/s41598-023-28037-w. Sci Rep. 2023. PMID: 36653468 Free PMC article.
-
Deciphering the Basis of Molecular Biology of Selected Cardiovascular Diseases: A View on Network Medicine.Int J Mol Sci. 2022 Sep 28;23(19):11421. doi: 10.3390/ijms231911421. Int J Mol Sci. 2022. PMID: 36232723 Free PMC article. Review.
-
Highlights from the European society of cardiology congress 2020.J Thromb Thrombolysis. 2021 Jan;51(1):232-236. doi: 10.1007/s11239-020-02365-4. Epub 2021 Jan 6. J Thromb Thrombolysis. 2021. PMID: 33403568 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
